醛糖还原酶抑制剂细胞筛选模型的建立

目的：将糖尿病慢性并发症相关基因醛糖还原酶 (aldose reductase, AR) 基因与腺相关病毒(adeno associated virus, AAV) 表达载体pSNAV2.0重组，使其在HEK293细胞中表达，以基因工程表达的AR为靶向，建立醛糖还原酶抑制剂 (aldose reductase inhibitor, ARI) 细胞筛选模型。方法：首先采用酶切、连接等方法构建含有人AR基因序列的AAV表达载体pSNAV-hAR，将重组质粒转染HEK293细胞，通过活性测定、Western blot和免疫荧光检测目的基因转染及表达的情况。结果：PCR、酶切、DNA测序均证实表达质粒pSNAV-hAR构建正确。转染HEK293细胞后，一系列分析结果显示，腺相关病毒表达载体介导的AR真核细胞表达产物是具有功能活性的目的蛋白。应用经典醛糖还原酶抑制剂 Sobinil 和 Zopolrestat 对此模型进行了验证。结论：AR高表达细胞模型的建立，为进一步筛选ARI、探讨多元醇通路学说在糖尿病慢性并发症发病机制中的作用奠定了基础。针对先后建立的酵母细胞与真核细胞模型的特点及三种AR活性测定方法中的注意事项进行了讨论。

An Aldose Reductase Inhibitor Screening Model Constructed by Transfection of pSNAV-AR into HEK293 Cells

Objective:Aldose reductase,involved in the pathogenesis of diabetic complications,was recombinated with an adeno associated virus vector pSNAV2.0,and it was transfected into human embryonic kidney 293(HEK 293)cells.The gene engineering produced AR would be used as a target protein to screen aldose reductase inhibitors.Restriction endonuclease digestion and ligation procedures were performed to construct the AR expression plasmid vector pSNAV-hAR.Methods:After confirmation the recombinant plasmid by PCR,rest...